timothy sykes logo

Stock News

ImmunityBio Authorized to Roll Out ANKTIVA in Europe and Saudi Arabia

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 2/23/2026, 11:33 am ET 2/23/2026, 11:33 am ET | 4 min 4 min read
ImmunityBio Authorized to Roll Out ANKTIVA in Europe and Saudi Arabia Thumbnail

ImmunityBio Inc. stocks have been trading up by 13.63 percent amid positive sentiment from promising trial results announcement.

Candlestick Chart

Live Update At 11:32:47 EST: On Monday, February 23, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 13.63%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview:

In recent financial movement, ImmunityBio has witnessed a notable uptick in their stock price. After the European Commission gave a nod to ANKTIVA and BCG combination for regions across Europe, the stock surged by a staggering 29.1% on Feb 18, 2026. This significant jump reflects burgeoning buying interests circulating amongst traders and the wider market.

Despite operating at a negative EBIT margin that stands at -319.5%, ImmunityBio has managed to maintain a promising current ratio of 5.8, indicating a strong ability to offset immediate liabilities. The company’s gross margin soared to 99.6%, an impressive figure in the biotech sphere.

Due to the rise in ImmunityBio’s share prices, triggered by the positive news surrounding European and Saudi authorizations, the trading activity drew a remarkable inflow of transactions. The stock traded within a volatile range with the highest recorded price peaking at $11 on Feb 23, 2026, before closing at $9.89.

Market Reactions:

The latest authorization from the European Commission highlighted a pivotal moment for ImmunityBio. As ANKTIVA expands its regional foothold, the maneuver resonates deeply with market analysts, promising a diverse portfolio of products reaching a wider consumer base across 33 countries. Investors have displayed remarkable confidence, evident from the brisk trading and abrupt surge in stock value.

Through their strategic accords with pharmaceutical giants like Accord Healthcare in Europe, ImmunityBio is taking firm steps towards broader commercialization pathways. An intriguing subplot unfolds as they set up a Dublin-based subsidiary to aid further growth, promising a tangible footprint in Europe’s robust healthcare market.

In parallel, the Saudi Food and Drug Authority’s green light poised the company for potential success in MENA regions. Tackling the BCG shortage problem with innovative rBCG solutions, ImmunityBio is aligning its operations with local needs, situating itself at a competitive advantage. Establishing direct lines of distribution through partnerships with Biopharma and Cigalah Healthcare, their product lines for bladder and lung cancers target a critical regional healthcare demand.

More Breaking News

Conclusion:

ImmunityBio is dynamically navigating through international waters to carve out an expansive market niche. In the world of trading, it’s crucial to adapt and learn, as millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” With the European and Saudi authorizations for ANKTIVA in tow, the strategic momentum gained is likely to sustain upward pressures on its stock trajectory. Bolstered by highly favorable market sentiments, ImmunityBio manifests a case study in how tactical shifts and global alignments can unlock immense growth potential, cementing its allure to the trading community.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”